Campylobacter

If you have had several days of bad diarrhea, especially with fever, cramping, or blood in the stool, the question you actually want answered is not just "is this a bug?" but "which bug, and does it need antibiotics?" This stool test answers that question directly for one of the most common bacterial causes of food-borne illness.

Knowing whether Campylobacter (a bacterium most often picked up from undercooked chicken, unpasteurized milk, or contaminated water) is responsible changes what happens next, from whether you need targeted antibiotics to whether you should be watched for rarer complications later. Catching it correctly also keeps you from being prescribed antibiotics you do not need.

What Campylobacter Is

Campylobacter is a curved bacterium with a particular cell-wall structure (called gram-negative) that lab tests use to classify it. It lives naturally in the guts of birds, cattle, and other animals, and reaches humans mainly through contaminated food or water. The test does not measure a hormone or protein your body makes; it looks for the bacterium itself, its DNA, or its antigens (the surface molecules the immune system recognizes) in your stool.

Most people who pick it up develop watery or sometimes bloody diarrhea, abdominal pain, and fever within a few days. The illness is usually self-limited and clears within about two weeks, but a meaningful minority end up hospitalized, develop bloodstream infection, or are left with longer-term gut or nerve problems.

Acute Gastroenteritis

Acute Campylobacter infection is the most common bacterial cause of gastroenteritis in many high-income countries, and it is also among the most common worldwide. In a large Chilean dataset of 16,582 stool specimens screened by molecular testing, Campylobacter was the most frequently detected bacterial enteric pathogen, found in 8.5% of samples. In South African children under two, Campylobacter antigen was detected in 13.2% of stools and was significantly more common in diarrheal than non-diarrheal samples (20.4% vs 12.4%).

Severe presentations are not rare. In a French hospital study, bloody diarrhea was a strong independent predictor of a positive stool PCR result, with about 16 times higher odds compared to non-bloody cases. In children, Campylobacter infection was about 3.6 times more likely than other enteritis to trigger a surgical consultation or imaging, because the abdominal pain can mimic appendicitis.

Hospitalization and Bloodstream Infection

A Danish registry of more than 50,000 bacterial gut infections found that about 1 in 10 people with Campylobacter (10.8%) were hospitalized. A more recent 2026 pooled meta-analysis put the global hospitalization rate slightly higher, at about 13.8% (95% CI 9.6-18.6%). In an Australian hospital dataset of 685 admissions, bacteremia (bacteria in the blood) occurred in 4.1% and acute kidney injury in 3.6%.

When Campylobacter does spread to the blood, it gets dangerous. In an Israeli case-control study, 30-day death rates were 6 times higher with bloodstream infection compared to standard enteritis (12% vs 2%), and intensive care use was also higher. A French series of 23 hospitals found 30-day mortality of 15% among Campylobacter bloodstream cases, mostly in older or immunocompromised people. A larger French multicenter study of 592 patients across 37 hospitals later reported a 30-day mortality of about 11.7%, putting the realistic range somewhere between roughly 1 in 10 and 1 in 6 of these severe cases.

Who Is at Highest Risk

Across Australia, Canada, and the United States, adults aged 65 and older are hospitalized for Campylobacter at much higher rates than younger adults, with risk climbing further with each decade. In one Australian hospital cohort, about a third of admissions (34.5%) had underlying medical conditions, and those patients were significantly more likely to develop electrolyte problems, low blood pressure, kidney impairment, or confusion.

Immune-system problems also matter. In a French study of people with hypogammaglobulinemia (low antibody levels) on immunoglobulin replacement therapy, Campylobacter was detected in 15.1% of patients, and positives had higher levels of fecal calprotectin (a stool marker of gut inflammation), suggesting active infection rather than silent carriage.

Long-Term Complications

Even after the diarrhea clears, Campylobacter can leave a mark. A long-term follow-up from a Minnesota outbreak cohort found that about 1 in 5 previously healthy people (21%) met criteria for post-infectious irritable bowel syndrome 6 to 9 months after infection. A 2023 pooled analysis put the average risk much lower, at about 1 in 22 cases (4.48%), and major reviews place the general post-infectious IBS rate after bacterial enteritis somewhere in the 5 to 10% range, with hospitalization during the acute illness raising risk.

Reactive arthritis (joint pain triggered by an infection elsewhere in the body) develops in roughly 1 to 3 in 100 cases across multiple meta-analyses. Guillain-Barré syndrome, a rare nerve disorder that can cause weakness or paralysis, is harder to pin down: a 2023 pooled analysis put the risk at about 1 in 1,400 cases (0.07%), while major reviews estimate it closer to 1 to 2 in 10,000 cases (0.01 to 0.02%). Either way, it is a rare but serious complication. A Swedish national cohort found about a 6-fold higher risk of reactive arthritis and nearly a 3-fold higher risk of ulcerative colitis in the year after Campylobacter infection.

Pediatric Disease and Growth

In young children in low-resource settings, Campylobacter is so common that even cases without obvious diarrhea matter. A multi-country MAL-ED analysis linked subclinical Campylobacter infection to lower height-for-age at age 2 (a length-for-age Z-score reduction of about 0.17 units), placing it alongside Shigella and Giardia as a meaningful contributor to childhood stunting.

Why the Testing Method Matters

Not all Campylobacter stool tests give the same answer. Traditional stool culture, the legacy method, is technically demanding because the bacterium is fragile, requires special low-oxygen growth conditions, and takes 48 to 72 hours. In a 1,552-specimen study, culture missed 28% of true positives, for a sensitivity of about 72%. In a parallel comparison against multiplex PCR in more than 4,500 samples, culture caught only about half of the positives (50.7%) while PCR caught 99.5%.

Modern multiplex PCR panels, like the FilmArray Gastrointestinal Panel, are highly sensitive and specific for Campylobacter (sensitivity around 97% and specificity around 98% in published evaluations) and test many other diarrheal pathogens at the same time. There is a caveat worth knowing about: a 2025 surveillance study from Wisconsin raised concerns about false-positive Campylobacter results from this panel, with culture or melting-curve analysis confirming only about 62% of panel-positive specimens. For high-stakes decisions, confirmation by a second method is reasonable. Rapid antigen tests vary more, with newer assays reaching 93 to 96% sensitivity and culture-level specificity, while older antigen tests had positive predictive values as low as 41% and produced many false positives in some hospital settings.

Sources: Buss et al. 2019; Porte et al. 2023; Fitzgerald et al. 2016.

What this means for you: a negative routine culture is not the same as a confirmed negative if you have ongoing diarrhea. If your symptoms are severe or persistent, ask whether the lab is using a molecular gastrointestinal panel rather than culture alone. If a molecular panel is positive but the clinical picture does not fit, ask whether the result has been confirmed.

Species Are Not Always the Same

Most clinicians think of "Campylobacter" as C. jejuni or C. coli, but stool research shows the genus is broader than that. In a multicountry infant study, less than half of all Campylobacter infections were C. jejuni or C. coli. Shotgun sequencing of Peruvian children's stools found that more than 65% of positive samples contained co-infections with multiple Campylobacter species, including C. upsaliensis, C. concisus, and a newer species called Candidatus Campylobacter infans.

This matters because some species, like C. upsaliensis, are inhibited by the antibiotics in standard culture media and can be missed entirely. C. concisus has been linked to longer-lasting diarrhea and to microscopic colitis: in one cohort, 80% of C. concisus patients had diarrhea lasting more than two weeks, and 12% were eventually diagnosed with microscopic colitis (a type of chronic inflammation of the colon) after 6 months. A later Danish population-based study reported an even stronger link, with a 6.2% absolute risk of microscopic colitis and a hazard ratio of about 32 after C. concisus detection.

When Results Can Be Misleading

A few situations can produce a misleading stool result. The most important factors are method and timing, not biology:

• Stool culture limitations: Campylobacter is fragile and dies during transport and handling, so a negative culture from a delayed or older specimen does not rule out infection. Modern PCR panels are far less sensitive to specimen age.
• Late testing: One multicenter study of a rapid antigen test found that positive concordance dropped to 50% when stool was collected 6 or more days after symptom onset, because the bacterial load falls as the illness resolves.
• Recent antibiotic use: Antibiotics taken before testing can suppress bacterial growth and lower the chance of recovering an organism, especially on culture. In hospitalized patients, prior antibiotic exposure was a confounder of stool pathogen detection.
• Antigen test cross-reactivity: Older stool antigen tests can produce false positives, sometimes triggered by other pathogens like C. difficile or norovirus. One quality-improvement audit found that 84% of positives from one rapid antigen assay were not confirmed when retested with a molecular panel.
• Molecular panel false positives: A 2025 study found that only about 62% of FilmArray-positive Campylobacter results were confirmed by culture or melting-curve analysis, so isolated positives without matching symptoms may warrant confirmation.

Proton Pump Inhibitors and Other Drug Effects

Some medications change how susceptible you are to Campylobacter in the first place, rather than how the assay performs. Proton pump inhibitors (acid-suppressing drugs like omeprazole) reduce stomach acid, which normally kills incoming bacteria. Reviews report relative risk of Campylobacter infection ranging from about 3.5 to nearly 12 times higher in PPI users compared to non-users, with a pooled odds ratio of about 5 in meta-analysis. Broad-spectrum antibiotics also reshape gut bacteria in ways that can influence both susceptibility and detection.

What to Do If Your Result Is Positive

A positive Campylobacter stool test is not, by itself, a prescription for antibiotics. Most healthy adults with mild to moderate symptoms recover on their own within about two weeks with rehydration alone. Antibiotics, typically azithromycin, are reserved for severe disease (high fever, bloody stools, prolonged or worsening symptoms), people who are immunocompromised, very young or very old patients, and those with bloodstream infection. PCR-based testing has been shown to help clinicians choose antibiotics more accurately and to reduce unnecessary antibiotic use when nonbacterial causes are found instead.

Beyond treatment, a positive result is a signal to think about companion testing and follow-up. If symptoms are severe or if you have an underlying immune problem, blood cultures may be warranted to check for bloodstream infection. Inflammatory markers like CRP (a blood test for body-wide inflammation) and fecal calprotectin (a stool marker of gut inflammation) help judge how active the infection is. Multiplex GI panels can identify co-infections that change management.

Antibiotic choice deserves close attention. Ciprofloxacin used to be the standard first-line option, but Campylobacter resistance to fluoroquinolones now exceeds 25 to 50% in many parts of the world, including parts of Europe, Asia, and the Americas. That makes empiric ciprofloxacin unreliable in most settings and is one of the main reasons azithromycin is now usually preferred for severe disease. If treatment is needed, ask whether the lab can grow the isolate and run susceptibility testing to confirm the choice.

Repeat Testing and Follow-Up

Unlike a chronic disease marker, this is not a number you trend month to month. The most useful repeat testing scenarios are specific. If symptoms persist or worsen despite treatment, a repeat stool test (preferably by a multiplex molecular panel) can confirm whether the original organism has cleared, whether a co-infection was missed, or whether a different pathogen has emerged. People in food handling, healthcare, or childcare roles may need documented clearance before returning to work, depending on local regulations.

Because Campylobacter has been linked to longer-term complications, the more useful thing to track after infection is your own symptoms over the following months. New or persistent gut symptoms after an episode can signal post-infectious IBS, and new joint pain or weakness should prompt evaluation for reactive arthritis or, very rarely, Guillain-Barré syndrome.